4 Stocks Where Promoters are Buying Stake

If you've been tracking promoter activity over the past few years, you would have noticed that 2025 took the trend to a whole new level.

Promoter selling crossed Rs 1.5 trillion (tn) last year, setting a fresh all-time high and extending a three-year streak of Rs 1 tn+ selling.

It's easy to panic when numbers seem so large but seasoned investors know that context matters. Not every sale signal trouble.

While promoter holding across companies is trending lower, some promoters are quietly buying from the open market. This is a strong show of conviction in their own businesses.

These transactions aren't just numbers on a screen. Behind them are people with skin in the game, betting on the upside they see before the rest of the world catches on.

If you would like to know more, join Richa Agarwal - Equitymaster's smallcap editor - in an online discussion about promoter buying in Indian stocks.

In this editorial, let's look at four recently listed stocks where promoters are buying stake from the open market.

#1 Enviro Infra Engineers

First on the list is Enviro Infra Engineers.

Enviro Infra Engineers specialises in providing comprehensive water and wastewater management solutions across India. The company delivers end-to-end services that meet the critical needs of both municipal and industrial sectors.

It offers turnkey projects of sewage treatment plants, sewerage systems, water treatment plants, water supply systems, common effluent treatment plants, etc. The company's promoters increased stake in the December 2025 quarter to 70.13%.

Coming to its financials, Enviro Infra's sales and net profit have grown at a CAGR of 62% and 102% in the past 5 years.

The ROE and ROCE have averaged 34% and 45% during the same time period.

Looking ahead, Enviro Infra is projecting revenue to grow more than 15% this year and net profit to grow over 20%. Its order book is about Rs 20 bn, offering revenue visibility of around 2 years.

The company has a huge tailwind in its favour, backed by government policies. It plans to capitalise on schemes like AMRUT 2.0, the Namami Gange Program, the National River Conservation Plan, and the National Plan for Conservation of Aquatic Ecosystems.

The company is also focusing on expanding its presence across India to become a national player. Increasing the project size to earn better margins is another growth strategy.

Enviro Infra launched its IPO in November 2025 and received a huge oversubscription of 91 times. Since then, its stock price has fallen around 8%.

#2 Indo Farm Equipments

Second on the list is Indo Farm Equipments.

Indo Farm Equipment is into manufacturing and marketing of Pick-N-Carry cranes of 9-30 tonnes capacity plus mobile tower cranes.

It's also engaged in manufacturing of tractors, cranes, harvester combines, engines and diesel gensets at its plant located in Baddi, Himachal Pradesh.

Over the years, Indo Farm has established a good track record due to its wide dealer network. It has an annual installed capacity of 12,000 tractors and 1,280 cranes at its existing plant.

It also has an in-house NBFC - Barota Finance - that facilitates product financing.

In the most recent December 2025 quarter, the company's promoters increased stake in the company to 69.53%.

Coming to its financials, Indo Farm's sales and net profit have grown at a CAGR of 10% and 37% over the past 5 years.

The ROE and ROCE have averaged 5% and 11% respectively.

At present, around 95% of the company's revenue comes from the tractor division and mobile crane division.

The demand for tractors in India is determined by multiple variables, and with demand expected to improve in the coming years, it can materially affect the company's margins.

The company is also looking to expand internationally. It derives 10% of its total revenue from international markets at present.

Indo Farm Equipment raised Rs 2.6 bn through its IPO in January last year. Since listing, the stock price has moved down by 20%.

#3 Senores Pharma

Third on the list is Senores Pharma.

Senores Pharmaceuticals is a global research driven formulation focused company that derives a major share of its revenue by developing and making pharma products for regulated markets of the US, Canada, and UK across various therapeutic areas.

These include infertility, cardiovascular, CNS, antidepressants, endocrine, SSRI (Anti-depressants), calcium blockers, muscle relaxant, respiratory, pain management, and oncology.

These markets account for over 60% of its revenue. Within regulated markets, the US accounts for 70% of its revenue.

The company also has exposure to 40+ emerging markets with branded generics.

In the December 2025 quarter, the promoters increased stake in the company to 45.8%. In fact, the promoter buying has been consistent for the past two quarters.

Coming to its financials, Senores Pharma's sales and net profit have grown at a CAGR of 204% and 289% over the past 3 years.

The ROE and ROCE has averaged 14% and 13% during the same time.

Along with a strong owned and acquired product portfolio as well as a foothold in CDMO, the company also has developed marketing partnerships with various global and domestic pharma companies get into markets for its formulations.

The company's management has guided for 50-60% growth at the topline level and 100% at net profit level in FY26, due to a growing portfolio across segments, growth in branded generics and improvement in profitability.

Senores Pharma was listed in December 2024. It offered 14.9 m shares, of which 2.1 m were under offer for sale, while fresh issue comprised of 12.8 m shares (Rs 5 bn fresh issue).

The issue price was Rs 391 per share and it listed at Rs 594 per share.

Here's the share price movement since listing...

#4 Suraksha Diagnostic

Last on the list is Suraksha Diagnostic.

Incorporated in 2005, Suraksha Diagnostic provides integrated and comprehensive diagnostic services in pathology and radiology.

It also provides medical consultation and genomics testing services. It is one of the largest diagnostic chains in Eastern India. The company follows a 'Hub-and-Spoke' business model.

Their promoters have over three decades of experience in the diagnostic services business and they have tied up with more than 10,000 doctors.

It generates around 90% of its revenue from walk-in customers, which has led to a strong brand presence and established market position in West Bengal.

In the December 2025 quarter, the company's promoters increased stake to 48.98%, as compared to 48.88% in September 2025. Prior to this, they had increased stake from 48.78%.

Coming to its financials, Suraksha Diagnostic's sales and net profit have grown at a CAGR of 10% and 15% over the past 5 years.

The ROE and ROCE have averaged 10.5% and 17% during the same time period.

Suraksha Diagnostic is now aiming to drive inorganic growth through selective acquisitions of regional diagnostic centers. Recently, it acquired a 63% stake in Fetomat, a prenatal and fetal medicine clinic.

It's also expanding its B2B segment and aims to strengthen partnerships with hospitals and insurance providers.

The company raised around Rs 8.5 bn from its IPO in December 2024, with the entire offer being an offer for sale.

Conclusion

When promoters buy shares in their own companies, it's a sign of their belief in the business.

In the four stocks discussed here, promoters are putting their money where their mouth is, even in tough market conditions.

But don't rely solely on this. Promoter buying and selling is useful but not enough on its own.

Investors should evaluate the company's fundamentals, corporate governance, and stock valuations as key factors when conducting due diligence before making investment decisions. Check industry trends, debt levels, and broader market conditions too.

If you want to track more stocks where insiders are buying check out our Insider Buying Screener to spot potential opportunities before the crowd.

Happy investing.

Disclaimer: This article is for education purposes only. It is not a recommendation and should not be treated as such. Learn more about our recommendation services here...